Treatment for neoplastic diseases
Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects.
1 . A method of stabilizing a progressive cancer in a human patient having cancer that has progressed after treatment with chemotherapy, radiotherapy, or biologic agents, the method comprising the step of repeatedly administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-interleukin-1alpha (anti-IL-1α) antibody at least until the progression of the cancer has been stabilized.
2 . The method of claim 1 , wherein the human patient's progressive cancer is metastatic, and the step of repeatedly administering the pharmaceutical composition results in a decrease in the tumor burden in the patient.
3 . The method of claim 1 , wherein the progressive cancer is metastatic colorectal cancer.
4 . The method of claim 2 , wherein the progressive cancer is metastatic colorectal cancer.
5 . The method of claim 1 , wherein the progressive cancer is metastatic non-small cell lung cancer.
6 . The method of claim 2 , wherein the progressive cancer is metastatic non-small cell lung cancer.
7 . A method of reducing the size of a tumor in a human patient with nasopharyngeal carcinoma that was previously treated with chemotherapy, radiotherapy, or biologic agents, the method comprising the step of repeatedly administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-IL-1α antibody at least until the size of the tumor is reduced.
8 . The method of claim 7 , wherein the patient has at least one symptom selected from the group consisting of fatigue, fever, sweats, and ascites, and the step of repeatedly administering the pharmaceutical composition results in a decrease in the at least one symptom.
9 . A method of stabilizing Castleman's disease in a human patient, the method comprising the step of repeatedly administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an anti-IL-1α antibody at least until the progression of the Castleman's disease has been stabilized.